81 results about "Hyperalgesia" patented technology

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.

The invention provides for compositions and methods of reducing pain in a subject by administering a combination of mu-opioid receptor agonist, kappa1-opioid receptor agonist and a nonselective opioid receptor antagonist in amounts effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The invention also provides for methods of enhancing an analgesic effect of treatment with an opioid-receptor agonist in a subject suffering from pain while reducing an adverse side effect of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment with an opioid-receptor agonist in a subject suffering from pain while reducing an adverse side effect of the treatment. The invention further provides for methods of promoting the additive analgesia of pain treatment with an opioid-receptor agonist in a subject in need while reducing an adverse side effect of the treatment.

The present invention provides methods of treatment of patients suffering from the complications of blood sugar disorders: diabetic peripheral neuropathy and diabetic nephropathy by administration of IGF-1 via protein therapy or gene therapy. It relates to methods of treating an individual having a diabetic disorder or a hyperglycemic disorder, comprising administering to the individual an effective amount of a DNA vector expressing IGF-1Eb or IGF-1Ec in vivo or an effective amount of at the IGF-1Eb or IGF-1Ec protein in the early hyperalgesia stage or in patients that have advanced to the hyposensitivity stage. Treatment at the early hyperalgesia stage prevents subsequent hyposensitivity with increases or maintenance of sensory nerve function. IGF-1Eb or IGF-1Ec treatment also increases muscle mass and improves overall mobility, which indicates a treatment-related improvement in motor function. Treatment with IGF-1Eb or IGF-1Ec at the hyposensitivity stage reverses hyposensitivity and improves muscle mass and overall health. Systemic IGF-1 provides a therapeutic modality for treating hyposensitivity associated with DPN. In addition, IGF-1Eb or IGF-1Ec provides a therapeutic modality for treating diabetic nephropathy. IGF-1Eb or IGF-1Ec improves renal function as evidenced by a modulation in serum albumin concentration and a reduction in urine volume and protein levels. IGF-1Eb or IGF-1Ec also reduces diabetic glomerulosclerosis.

The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.

ABSTRACTA pharmaceutical composition comprises a combination of a selective or specific COX 2 inhibitor or a pharmaceutically acceptable salt or derivative thereof and an opiate or a pharmaceutically acceptable salt or derivative thereof, for example a combination of meloxicam and codeine, as active ingredients, and a pharmaceutically acceptable carrier. It may include a centrally-acting cyclo-oxygenase inhibitor such as paracetamol or its pharmaceutically acceptable salts or derivatives. The pharmaceutical compositions are used in methods of providing symptomatic relief or treatment of pain, in an algesic and/or hyperalgesic state, with or without fever, in particular that associated with inflammation such as that associated with trauma, osteoarthritis, rheumatoid arthritis, non-inflammatory myalgia or dysmenorrhoea

Compounds having formula (I)

or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R¹, R² and R³ are as defined herein. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.

The role of the epsi isozyme of protein kinase C ("PKCepsi") in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKCepsi, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKCepsi and PKCepsi-independent analgesic agent are disclosed.

The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTMI, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception.

The invention discloses a new use of methyl liensinine. Methyl liensinine respectively regulates M8 and V1 subtype transient receptor potential ion channels (TRPM8 and TRPV1 for short) of mammal including human, so as to prepare medicine for treating related diseases joined by the ion channels (such as cold hyperalgesia, parkinsonism, nociceptive bladder syndrome, chronic obstructive lung diseaseand tumours of skin, prostate, breast, lung and colon). The action strength of methyl liensinine of the invention is higher than that of menthol.

This invention describes compounds and methods that can be used to treat, reverse, or avoid hyperalgesia.

The present invention provides a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, wherein the spacer is bonded to the two opioid molecules via an ether bond. Pharmaceutical compositions comprising such a buprenorphine dimer drug are also disclosed, and the use of such compounds in the treatment of gastrointestinal hyperalgesia generally and in particular diarrhea-predominant irritable bowel syndrome.

The invention discloses a TNFR1 gene recombinant adenovirus. The adenovirus contains siRNA expressed by an interference TNFR1 gene of a nucleotide sequence shown in SEQ ID No.1, the siRNA is connected to the place below a U6 promoter of shuttle plasmid pHBAd-U6-GFP to prepare an adenovirus shuttle plasmid, and then the adenovirus shuttle plasmid and a skeleton plasmid pHBAd-BHG are subjected to cotransfection 293 cells to obtain adenovirus Ad-TNFR1 shRNA. The TNFR1 gene recombinant adenoviru is used for blocking or reducing TNFR1 expression and blocking a biological effect produced through TNF in a new way, so that tool medicine is designed to explore the effect of TNFR1 in hyperalgesia generation and the intracellular action mechanism, and medicine for preventing inflammatory factors from activating a receptor is designed to weaken the hyperalgesia effect caused after receptor activation.

A method for treating opiate induced tolerance or opiate induced hyperalgesia in a subject is closed. More specifically, the method provides for reducing ceramide levels with an agent thereby treating opiate induced antinociceptive/analgesic tolerance or hyperalgesia in a human or non-human subject. The method further allows for improved pain management in subjects suffering from chronic pain as well as treatment for opiate induced disorders.

The present invention relates to a method of treating hyperalgesia in a subject, which involves administering to a subject an amount of a TRPV1 agonist compound that selectively inhibits hyperactive nociceptive neurons. The present invention also relates to a method of selectively inhibiting hyperactive nociceptive neurons. Also disclosed is a method for reducing the electrical activity of hypersensitive neurons sensitized to TRPV1. The present invention also relates to a method for identifying candidate compounds that selectively inhibit hyperactive nociceptive neurons. Also disclosed is a pharmaceutical composition.